AccuMetab™ Human CYP4F2 Enzyme, Catalytically Active with Cytochrome b5
CAT#: ITS-0426-YL75
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP4F2 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Cytochrome b5 greatly accelerates the catalytic rate of CYP4F2, an enzyme critical for vitamin K and arachidonic acid metabolism. This high-efficiency system is utilized to investigate complex lipophilic drug interactions and map highly specialized Phase I oxidative pathways.
Key Features
Cytochrome b5 supplemented for max catalytic turnover; Accelerates vitamin K and arachidonic acid conversion; Maps highly specialized lipophilic Phase I pathways; Supplied in controlled, low-reductase formats
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.